Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Informationsteknik |
| Industri | Programvara |
Helsinki, Finland - July 18, 2024 - Nordhealth is pleased to announce that it has achieved EBITDA-CAPEX breakeven in Q2 2024, excluding one-off, non-recurring items. This milestone, initially projected for Q1 2025 as outlined in the Q4 2023 Investor Presentation on March 5, 2024, and reaffirmed in the 2023 Annual Report on April 12, 2024, has been reached ahead of schedule.
Preliminary figures indicate that Nordhealth's EBITDA-CAPEX, excluding one-off, non-recurring items, will be slightly positive in Q2 2024. However, as planned, the company does not expect to maintain EBITDA-CAPEX breakeven in H2 2024 and the full year of 2024.
This accelerated improvement is primarily driven by higher-than-forecasted implementation and recurring revenues in our Veterinary business unit.
Nordhealth continues to anticipate 15-20% growth in recurring revenue in 2024 compared to 2023, calculated at a constant currency rate as of December 31, 2023. Further information on profitability guidance will be provided in our Q2 2024 Investor Presentation on August 20, 2024.